HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate-Palmolive Records $518M Filorga Impairment, Launches Global Savings Initiative

Executive Summary

Colgate-Palmolive’s 2022 Global Productivity Initiative should result in annualized pre-tax savings in the range of $90m to $100m, the New York firm said in its fourth quarter earnings presentation on 28 January. The Filorga impairment charge reflects the pandemic’s impact on duty-free and travel retail channels since Colgate acquired the France-based, premium skin-care brand in 2019 for nearly $1.7bn.

You may also be interested in...



Colgate, P&G Extend Teeth Whitening Lines

Colgate Optic White line with Pro Series teeth-whitening toothpaste contains 5% hydrogen peroxide; P&G’s Crest Whitening Emulsions + Overnight Freshness offers convenience of overnight use.

Colgate’s Prioritizes Oral Care Sales Growth In Countries With Low Per Capita Daily Brushing

Colgate expects countries where oral care isn’t a daily habit per capita are biggest opportunities for growth. Half its sales growth is in e-commerce and other channels that don't show up in market data.

E.l.f. Cosmetics Will Be Selectively Less Affordable Come March

E.l.f. will raise prices by $1 across SKUs where it has the most pricing power, while maintaining its lowest-priced items where they are now, CEO Tarang Amin said during the firm’s fiscal 2022 third-quarter earnings call. The company raised guidance for the full year, now targeting net sales up to $379m.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel